Past Issues
See what you've been missing. Browse every issue of our free, daily briefing.
An FDA panel just voted 7-2 to screen for 50+ cancers with a blood draw
A single tube of blood that screens for over fifty types of cancer just cleared its biggest regulatory hurdle. Meanwhile, Big Pharma is writing billion-dollar checks for science that doesn't exist yet, Europe's biotech leaders are sounding alarms, and the Pentagon just hired a biotech incubator. Buckle up.
A drug just beat one of the fastest-killing diseases in medicine (p=0.0005)
A rare form of ALS that kills most patients within two years just got its first real shot at a treatment, and the clinical data is about as clean as it gets. Meanwhile, a drug that aced two Phase 3 trials somehow tanked its stock, and the U.S. government told lab mice their days are numbered.
FDA staff found zero red flags for a blood test that spots 12 deadly cancers
A multi-cancer blood test just sailed through its toughest regulatory checkpoint yet, and tomorrow's advisory panel vote could set the rules for an entire industry. Meanwhile, the obesity drug wars are escalating on every front: new winners, new losers, and a strategy shakeup that cost 4,000 people their jobs.
A sleep drug just accidentally improved ADHD symptoms. Huh.
A wakefulness drug that sharpens focus instead of just keeping you awake, a thyroid trick that lifts bipolar depression without touching serotonin, and a $1.6 billion check to pick a fight with Novartis. Today's issue is packed with mechanisms nobody saw coming.
Novo Nordisk just erased half its name. The reason is revealing.
The Danish pharma giant behind Ozempic and Wegovy dropped five letters from its name, and the reasoning tells you everything about where the GLP-1 era is headed. Meanwhile, AstraZeneca is reportedly negotiating a $15 billion deal for a single cancer drug that beat Keytruda head-to-head.
One shot of CRISPR cut disease attacks by 87%. Gene editing just got real.
A single IV infusion that rewrites your DNA and nearly eliminates a genetic disease sounds like science fiction, but Intellia just proved it works in a pivotal trial. Meanwhile, an $8 billion nuclear medicine mega-deal, a cannabinoid that doubled Ozempic's weight loss in mice, and Anthropic buying pipettes.
A $3.95M shot just became the first treatment for a fatal childhood disease
The FDA just approved a gene therapy that costs more than most houses for a disease that had zero treatments until yesterday. Meanwhile, a kidney drug posted numbers so good that nephrologists are double-checking the spreadsheet, and big pharma kept writing billion-dollar checks for drugs that haven't touched a human.
Pfizer just dropped $10B on an obesity company with zero approved drugs
Pfizer wrote a $10 billion check for a three-year-old company that's never sold a single pill, and Wall Street responded with a collective shrug. Meanwhile, a cancer drug's mirror image is quietly rewriting the playbook for arthritis treatment, and Huntington's disease just got the most encouraging data it's seen in years.
AstraZeneca is willing to pay $15B for a drug most people can't pronounce
A single cancer drug is commanding a price tag that rivals some countries' GDP, and it might actually be worth it. Meanwhile, the deal blitz continues with over $30 billion in M&A hitting the tape today, the FDA is rewriting the rules for getting drugs into humans faster, and an AI-designed molecule just reached its make-or-break moment.
The flu vaccine just ditched 6 billion chicken eggs
The FDA just approved the first-ever mRNA flu vaccine, and it's not about the flu. It's about proving that the technology behind the COVID shot isn't a one-hit wonder. Meanwhile, Novo Nordisk walked away from a $285 million obesity deal, GSK wrote a $750 million check for a drug that doesn't exist yet, and a tiny biotech revived a mechanism that once destroyed careers.
An LSD pill just went 3-for-3 in Phase 3, and the FDA is next
A pharmaceutical-grade LSD tablet just aced its third consecutive late-stage trial, putting psychedelic medicine on a genuine runway to FDA approval. Meanwhile, a drug that technically failed its pivotal trial somehow got approved anyway, and Gilead's biggest oncology bet just faceplanted in lung cancer.
Three deaths just froze the hottest idea in autoimmune medicine
Autoimmune CAR-T therapy went from "next big thing" to existential crisis in a matter of weeks, after fatal immune reactions forced two pharma giants to hit pause. Meanwhile, a Chinese drug just did what no one thought possible: beat Keytruda head-to-head in lung cancer.
The first SMA drug that ignores the broken gene entirely just got approved
The FDA approved a muscle-targeted SMA therapy that doesn't touch the disease's root cause, and somehow that's exactly why it works. Meanwhile, gene therapy's safety crisis deepened, a cancer vaccine made history, and one FDA commissioner allegedly tried to kill a drug approval.
Biohaven signed a $795M deal. Nine days later, the FDA called.
A near-billion-dollar epilepsy deal just ran headfirst into the FDA's most unpredictable kind of risk, and the timing is almost comically brutal. Meanwhile, a tiny CAR-T trial went 20-for-20 in preventing cancer before it starts, BMS won't share its own good news, and biotech's backdoor to Wall Street is running out of keys.
The first AI-designed drug just entered its championship round
An AI-designed molecule just reached Phase III for the first time in history, and a $12 billion RNA bet just collapsed in the same week. Today's issue is a rollercoaster of billion-dollar conviction and billion-dollar humility.
Novartis spent $12B on a drug that just flopped its Phase III trial
A $12 billion acquisition thesis crumbled overnight when Novartis' flagship RNA drug missed its primary endpoint in myotonic dystrophy, dragging competitors down with it. Meanwhile, small cell lung cancer got its first real win in decades, and a CRISPR therapy is one FDA decision away from making history.
Merck just dropped $10B on a lung drug. The Keytruda clock is ticking.
Merck's $10 billion acquisition of Verona Pharma is the kind of deal that screams urgency: Keytruda's patent cliff is two years away, and the company just bet its respiratory future on a single COPD drug. Meanwhile, Novartis watched its own $12 billion acquisition stumble, a gene editor that doesn't cut DNA cured sickle cell, and Novo Nordisk gave Wegovy to first-graders. It's been a week.
Novo Nordisk just torched $3.4B on two failed drugs in one summer
Novo Nordisk killed two major pipeline programs in a matter of months, burning through billions in acquisition costs and leaving investors wondering if the GLP-1 giant can build anything beyond Ozempic. Meanwhile, an FDA approval could finally retire one of medicine's most medieval procedures.
A drug crushed its target by 80%. Patients didn't get better.
The most anticipated cardiovascular trial in years just delivered a gut punch: pelacarsen obliterated a genetic risk factor but failed to prevent a single heart attack. Meanwhile, celiac patients got their first real hope for a drug, and Lilly is rewriting the pricing playbook for its weight-loss juggernaut.
An 80% Lp(a) reduction and 8,323 patients later: nothing happened
The biggest cardiovascular trial in a decade just delivered a result that nobody in cardiology wanted to see. Novartis's pelacarsen obliterated Lp(a) levels, but heart attacks kept coming anyway, threatening billions in competing programs. Meanwhile, a blood test just rewrote the rules for breast cancer treatment, two pharma giants paused autoimmune CAR-T within days of each other, and America's only syphilis drug for pregnant women got recalled.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.